Novartis13d
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
Pharmaceutical Technology11d
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...
Pharmabiz11d
US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP
US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP: East Hanover Thursday, October 31, 2024, 12:00 Hrs [IST] Novartis an ...
Novartis Pharma AG: Novartis Scemblix FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
Managed Healthcare Executive12d
FDA Grants Accelerated Approval of Scemblix for Newly-Diagnosed CML
Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...
ThePrint on MSN12d
In Delhi hospitals, thalassemia patients suffer as life-saving Desferal scarce, set to become 50% costlier
Doctors & patients confirm acute shortage of the drug in hospitals, even as manufacturer Novartis maintains there is no ...
pharmaphorum4d
A history of Novartis
According to Novartis, the Glivec International Patient Assistance Program has provided free treatment to nearly 27,000 patients in over 80 countries who would otherwise not have had not access to ...